Alibaba

Alibaba taking the US Department of Defense to court over its inclusion on the Chinese Military Company list is the most aggressive legal challenge yet to Washington's corporate blacklisting programme. Being on the list does not trigger sanctions outright, but it chokes off US institutional investment, complicates banking relationships, and gives procurement officers cover to exclude you from contracts. Alibaba's argument will almost certainly rest on procedural grounds: that the designation process lacks due process and that its core e-commerce and cloud businesses bear no credible military connection. The risk for Washington is that a court ruling in Alibaba's favour forces the Pentagon to publish a more rigorous evidentiary standard, which would constrain the list's use as a broad-brush geopolitical lever. For UK investors still holding Alibaba ADRs or H-shares, a successful suit would remove a persistent discount; a failed one cements the political risk as permanent.

Zelos, backed by Alibaba, plans a $600 million Hong Kong IPO as Chinese tech companies return to public markets after two years of regulatory crackdowns. The timing tests whether international investors will re-embrace Chinese growth stories or remain skeptical of regulatory risks. Success could open the floodgates for other Alibaba portfolio companies seeking liquidity. The IPO also serves as a barometer for Hong Kong's ability to compete with US exchanges for high-growth tech listings.